Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

71.200
-4.900-6.44%
Volume:2.30M
Turnover:166.20M
Market Cap:14.17B
PE:-50.43
High:76.150
Open:76.000
Low:70.350
Close:76.100
52wk High:97.500
52wk Low:44.720
Shares:199.00M
HK Float Shares:198.00M
Volume Ratio:1.02
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.412
ROE:-27.61%
ROA:-9.92%
PB:9.59
PE(LYR):-50.43
PS:68.50

Loading ...

Nanjing Leads Biolabs Clarifies Award Grant to Executive Director is Exempt Connected Transaction Under HK Rules

Reuters
·
Aug 04

Leads Biolabs' Pd-L1/4-1Bb Bispecific Antibody Ind Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise

THOMSON REUTERS
·
Aug 03

LEADS BIOLABS-B shares climb nearly 6% as PD-L1/4-1BB bispecific antibody gets IND clearance for advanced colorectal cancer treatment

Stock News
·
Aug 03

LEADS BIOLABS-B Shares Shift with HK$364 Million in Custody Transfers, Representing 3.62% of Total

Stock News
·
Aug 03

Nanjing Leads Biolabs Co - Lbl-024 Receives Ind Approval from Nmpa for Metastatic Colorectal Cancer

THOMSON REUTERS
·
Aug 03

Nanjing Leads Biolabs Says China Regulator Clears IND for Lbl-024 in Metastatic Colorectal Cancer

Reuters
·
Aug 03

Movement Alert|LEADS BIOLABS-B Rises 5.11% in Regular Trading, Core Pipeline Cholangiocarcinoma Phase II Study Completes Full Patient Enrollment

Market Focus
·
Jul 31

LEADS BIOLABS-B (09887) Records 346 Million Hong Kong Dollar Share Transfer, Representing 3.39% of Total Shares

Stock News
·
Jul 31

Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Completes Patient Enrollment in Phase Ii Study for Biliary Tract Cancer, Further Demonstrating Breakthrough Potential in Immune-Cold Tumors

THOMSON REUTERS
·
Jul 30

Leads Biolabs completes full enrollment of 70-patient Phase II trial for bispecific antibody LBL-024 in first-line advanced biliary tract cancer

Bulletin Express
·
Jul 30

Nanjing Leads Biolabs Completes Enrollment in Phase II Opamtistomig Trial for Advanced Biliary Tract Cancer

Reuters
·
Jul 30

LEADS BIOLABS-B (09887) Records a Major Securities Transfer Valued at HK$746 Million, Representing 7.10% of Total Shares, with 13.76 Million Shares Moved from China Securities Depository and Clearing Hong Kong

Stock News
·
Jul 30

Hong Kong Stocks Update: LEADS BIOLABS-B (09887) Drops Over 7% Further, Kpc Pharmaceuticals Plans to Sell HKD 132 Million Stake, Founder Voluntarily Extends Lock-Up Period

Stock News
·
Jul 28

Movement Alert|LEADS BIOLABS-B Falls 5.51% in Regular Trading, Lock-Up Expiry Triggers Selling Pressure as Kunming Pharma Exits Position

Market Focus
·
Jul 28

KPC Pharmaceuticals to Divest Stake in Nanjing Leads Biolabs

MT Newswires Live
·
Jul 27

Hong Kong Stock Market Midday Review: Hang Seng Index Rises 0.81% as Xiaomi Leads the Blue Chips with a 7% Gain

Stock News
·
Jul 27

New Forecasts: Here's What Analysts Think The Future Holds For Nanjing Leads Biolabs Co., Ltd. (HKG:9887)

Simply Wall St.
·
Jul 23

LEADS BIOLABS-B Shares Surge Over 11%, Marking a 30% Gain in Three Days on ESMO Research News

Stock News
·
Jul 15

LEADS BIOLABS-B Shares Surge Over 15% as Key Drug Candidate LBL-024 Enters Priority Review

Deep News
·
Jul 14

Leads Biolabs Says Six Studies Accepted for Presentation at ESMO 2026

Reuters
·
Jul 13